Results 171 to 180 of about 933,669 (299)

Risk of primary Sjogren's Syndrome following human papillomavirus infections: a nationwide population-based cohort study. [PDF]

Front Immunol, 2022
Chen HH, Ma KS, Dong C, Chang WJ, Gao KR, Perng WT, Huang JY, Wei JC.   +7 more
europepmc   +1 more source

Methodology of the French National Study “Context of Sexualities in France” (CSF‐2023)

Perspectives on Sexual and Reproductive Health, EarlyView.
ABSTRACT Introduction The 2023 national survey “Context of Sexualities in France” (CSF‐2023) explores sexuality and sexual health in France. Methods Conducted between November 2022 and December 2023, CSF‐2023 is a cross‐sectional probability survey involving 21,259 respondents aged 15–89 in continental France.
Caroline Moreau, Aline Bohet, Armelle Andro, Yann Le Strat, Nathalie Bajos   +4 more
wiley   +1 more source

Need for gender-neutral human papillomavirus vaccination: Lessons from a retrospective epidemiologic investigation of human papillomavirus infections among outpatients presenting to a tertiary dermatology hospital in Central China from 2017 to 2024. [PDF]

IJID Reg
Zhou X, Mo H, Zhou Z, Xu Y, Li C, Tao X.
europepmc   +1 more source

AHCC^® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections. [PDF]

Front Oncol, 2022
Smith JA, Gaikwad AA, Mathew L, Rech B, Faro JP, Lucci JA, Bai Y, Olsen RJ, Byrd TT.   +8 more
europepmc   +1 more source

Triage Performance of FAM19A4/miR124‐2 Methylation: 18‐Month Follow‐Up Results From a Prospective Observational Study Within the Dutch Primary HPV‐Based Cervical Screening Program

International Journal of Cancer, Volume 159, Issue 10, Page 2463-2472, 15 November 2026.
ABSTRACT DNA methylation analysis of the genes FAM19A4 and miR124‐2 has emerged as a promising triage strategy for high‐risk (hr) human papillomavirus (HPV)‐positive women in cervical screening. This study reports a prospective evaluation of the diagnostic accuracy of FAM19A4/miR124‐2 methylation in a large population‐based primary HPV‐based screening ...
Lisanne Verhoef, Mila S. Griffioen, Maaike C. G. Bleeker, John W. J. Hinrichs, Albert G. Siebers, Albertus T. Hesselink, Chris J. L. M. Meijer, Renske D. M. Steenbergen, Johannes Berkhof, Daniëlle A. M. Heideman   +9 more
wiley   +1 more source

Multiple high-risk human papillomavirus infections exacerbate cervical lesion risk: epidemiological evidence from suining, Sichuan. [PDF]

Virol J
Jing Y, Chen J, Lin F, Huang X, Liu Y, Zhao M, Ye C, Zhao L, Liu X, Yang J.   +9 more
europepmc   +1 more source

Human papillomavirus infections among women with cervical lesions and cervical cancer in Yueyang, China: a cross-sectional study of 3674 women from 2019 to 2022. [PDF]

Virol J, 2023
Zeng M, Zhang X, He L, Liu X, Liu H, Deng R, Qiu B, Liu F, Xiao H, Li Q, Li W, Liu C, Ge Y.   +12 more
europepmc   +1 more source

Papillomavirus infections

, 2010
Sten H Vermund, Madhav P Bhatta, Vikrant V Sahasrabuddhe   +2 more
openaire   +1 more source

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer

International Journal of Cancer, Volume 159, Issue 9, Page 2336-2346, 1 November 2026.
ABSTRACT The incidence of human papillomavirus‐positive (HPV+) oropharyngeal cancer (OPC) has increased rapidly, and HPV early antigen serology has been proposed as a scalable and cost‐effective early detection test. HPV seropositivity can precede clinical presentation of OPC by several years, so additional surveillance procedures may be necessary to ...
Lucas Penny, Eric Yang Stutheit‐Zhao, Birgitta E. Michels, Fabian Rosing, Zhen Zhao, Yangqiao Zheng, Jinfeng Zou, Shao Hui Huang, Johnny Carlton, Andrew McPartlin, John R. de Almeida, David Goldstein, Andrew Hope, Ali Hosni, John Kim, Fei‐Fei Liu, C. Jillian Tsai, John N. Waldron, Anna Spreafico, Enrique Sanz‐Garcia, Lillian L. Siu, Tim Waterboer, Geoffrey Liu, Scott V. Bratman   +23 more
wiley   +1 more source

Targeting papillomavirus infections: high-throughput screening reveals an effective inhibitor of cutaneous β-HPV types. [PDF]

J Virol
Ibragimov R, Babok S, Lototskaja-Perepelenko E, Ivanova L, Mikhailava N, Zaikina L, Piirsoo M, Piirsoo A.   +7 more
europepmc   +1 more source